Overactive Bladder
📧 Sign up to get email alerts when something new happens for Overactive Bladder.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2007-07-12FDA Approved: VESICARE — Supplemental Application (Astellas Pharma US, Inc.)
The FDA approved a supplemental application for Vesicare (solifenacin succinate) submitted by Astellas Pharma US, Inc., updating the drug's …
-
CLINICAL_TRIALS research · 2007-05-30Clinical Trial Update: This is a Prospective, Randomized, Double-Blind Study Comparing Intravesical Injection of Botox® to Placebo. [Phase 2, Phase 3]
A prospective, randomized, double-blind trial comparing intravesical Botox injections to placebo for Overactive Bladder, spanning Phase 2 an…
-
CLINICAL_TRIALS research · 2007-05-17Clinical Trial Update: Safety and Applicability Study of a Novel Heat Flow Sensor Unit for Measuring Urinary Bladder Capacity
This document describes a safety and applicability study of a novel heat-flow sensor unit intended to measure urinary bladder capacity. The …
-
FDA approval · 2007-04-24FDA Approved: VESICARE — Supplemental Application (Astellas Pharma US, Inc.)
The FDA approved a supplemental application for Vesicare (solifenacin succinate) from Astellas Pharma US, Inc. under NDA 021518.
-
FDA approval · 2007-03-16FDA Approved: DETROL LA — Supplemental Application (Viatris Specialty LLC)
The FDA approved a supplemental application for DETROL LA (tolterodine tartrate) from Viatris Specialty LLC.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2007-03-16FDA Approved: TOLTERODINE TARTRATE — Supplemental Application (Mylan Pharmaceuticals Inc.)
The FDA approved a supplemental application for tolterodine tartrate submitted by Mylan Pharmaceuticals Inc., updating the product's labelin…
-
CLINICAL_TRIALS research · 2007-02-21Clinical Trial Update: Assessing the OAB-8 Questionnaire as a Tool to Measure Treatment Outcome [Phase 4]
This ClinicalTrials.gov update examines the OAB-8 questionnaire as a tool to measure treatment outcomes in Overactive Bladder in a Phase 4 s…
-
FDA approval · 2007-02-01FDA Approved: OXYBUTYNIN CHLORIDE — Supplemental Application (Strides Pharma Science Limited)
FDA approved a supplemental application for oxybutynin chloride (Strides Pharma Science Limited) under ANDA075079. This action authorizes th…
-
FDA approval · 2006-12-17FDA Approved: OXYBUTYNIN CHLORIDE — Supplemental Application (Upsher-Smith Laboratories, LLC)
FDA approved a supplemental application for oxybutynin chloride from Upsher-Smith Laboratories, indicating an updated or expanded approval f…
-
FDA approval · 2006-10-26FDA Approved: OXYBUTYNIN CHLORIDE — Supplemental Application (Chartwell Governmental & Specialty RX, LLC.)
FDA approved a supplemental application for oxybutynin chloride submitted by Chartwell Governmental & Specialty RX, LLC.
-
FDA approval · 2006-07-05FDA Approved: OXYTROL — Supplemental Application (Allergan, Inc.)
FDA approved a supplemental application for OXYTROL (oxybutynin) from Allergan, authorizing changes to the product via a supplemental submis…